Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 9, 2009

Wanbang to Advance D-Pharm’s Late-Stage Stroke Therapy in China

  • Wanbang Biopharmaceuticals and D-Pharm signed a licensing, co-development, and supply agreement for commercialization of the latter’s late-stage ischemic stroke therapy, DP-b99, in China. D-Pharm could earn up to $25.5 million in development, regulatory, and sales milestones.

    It will also receive royalties from sales of DP-b99 in China in exchange for exclusive supply of the drug to Wanbang. Up to $7 million of the milestone payments may be exchanged for royalties.

    D-Pharm is already carrying out a multinational Phase III trial with DP-b99 in acute stroke patients.  As part of the co-development arrangement in China, D-Pharm and Wanbang will jointly undertake a Phase III study in acute stroke patients, separate from D-Pharm’s Phase III study in North America, Europe, South Africa, and Israel. D-Pharm will have the right to use results from this trial to expedite regulatory clearance in other territories.

    DP-b99 is a membrane active chelator (MAC) derivative of the known calcium chelator BAPTA. D-Pharm claims the drug acts as a lipophilic chelator of calcium, zinc, and copper ions but sequesters metal ions only within and in the proximity of cell membranes.

    DP-b99 is also in early clinical development as a potential therapy for traumatic brain injury and for the prophylactic treatment of neurological damage associated with coronary artery bypass grafting.

    D-Pharm specializes in the development of drugs for brain disorders. The company’s lipid-based MAC technology is used to design small molecules that specifically function only within the lipid environment of cell membranes.

    D-Pharm is also exploiting another technology, D-RAP™ (regulated activation of prodrugs), for the rational design of new chemical entities that represent phospholipid derivatives of marketed drugs. Lead D-RAP candidate, DP-VPA, is a lipid-conjugated prodrug comprising valproic acid. DP-VPA has completed a Phase II trial in the treatment of epilepsy. Earlier-stage clinical studies are ongoing in bipolar disorder and migraine prophylaxis.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »